Form 4: Immix Biopharma Director Jane Buchan Reports Stock and Option Acquisitions Following Merger

Director Jane Buchan reports acquisition of Immix Biopharma stock and options related to the merger with Nexcella, Inc.

Summary

• Jane Buchan, a director of Immix Biopharma, reported the acquisition of 1,332 shares of common stock on May 15, 2024, and an additional 1,127 shares on May 20, 2024.
• These acquisitions are related to the merger of Nexcella, Inc. with Immix Biopharma, which became effective on May 20, 2024.
• Buchan also acquired stock options to purchase 20,436 shares and 24,153 shares of common stock at an exercise price of $2.47 on May 15, 2024.
• The stock options and restricted stock awards were issued to replace prior awards held in Nexcella, Inc.
• The restricted stock awards and stock options will vest in thirteen equal monthly installments, contingent upon continued service with Immix Biopharma.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard regulatory filing detailing stock and option acquisitions following a merger. The director's increased stake could be seen as mildly positive.

Positives

• The acquisition of shares and options by a director could be seen as a positive signal, indicating confidence in the company's future after the merger.

Future Outlook

The vesting of restricted stock awards and stock options is contingent upon the Reporting Person's continued service with the Issuer.

Industry Context

This Form 4 filing is a routine disclosure related to insider transactions, particularly in the context of a merger. It provides transparency into the holdings and transactions of company insiders.

Stakeholder Impact

• The transactions may have a minor positive impact on shareholder sentiment due to the director's increased investment in the company.

Key Dates